Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Reviewing the research presented at ACR Convergence 2024.
ARP members honored for significant contributions to rheumatology research, education and patient care.
Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Occupational therapist Cheryl Crow, who lives with rheumatoid arthritis, shares the ins and outs of what OT is and how it can help those with rheumatic conditions.
Dr. David D’Cruz’s research attempts to help patients make sense of chronic nightmares, an understudied symptom of lupus.
An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.